Direct-acting antivirals (DAAs) are safe and effective for the treatment of HCV infection. However, data regarding their efficacy in patients with Child-Pugh B cirrhosis are scarce and their capability in improving liver function is debated. The aim of our study was to assess the clinical benefits of treatment with DAA in subjects with Child-Pugh B cirrhosis.
Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort) / Gentile, I.; Scotto, R.; Coppola, C.; Staiano, L.; Amoruso, D. C.; De Simone, T.; Portunato, F.; De Pascalis, S.; Martini, S.; Macera, M.; Viceconte, G.; Tosone, G.; Buonomo, A. R.; Borgia, G.; Coppola, N.. - In: HEPATOLOGY INTERNATIONAL. - ISSN 1936-0533. - 13:1(2019), pp. 66-74. [10.1007/s12072-018-9914-6]
Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort)
Gentile I.;Scotto R.;Amoruso D. C.;Portunato F.;Viceconte G.;Tosone G.;Buonomo A. R.;Borgia G.;
2019
Abstract
Direct-acting antivirals (DAAs) are safe and effective for the treatment of HCV infection. However, data regarding their efficacy in patients with Child-Pugh B cirrhosis are scarce and their capability in improving liver function is debated. The aim of our study was to assess the clinical benefits of treatment with DAA in subjects with Child-Pugh B cirrhosis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
